KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Opko Health (OPK) over the last 16 years, with Q3 2025 value amounting to -$316000.0.

  • Opko Health's Exchange Rate Effect fell 11195.16% to -$316000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 17370.28%. This contributed to the annual value of -$3.2 million for FY2024, which is 91365.98% down from last year.
  • Opko Health's Exchange Rate Effect amounted to -$316000.0 in Q3 2025, which was down 11195.16% from $1.5 million recorded in Q2 2025.
  • Opko Health's 5-year Exchange Rate Effect high stood at $2.6 million for Q3 2024, and its period low was -$5.6 million during Q4 2024.
  • In the last 5 years, Opko Health's Exchange Rate Effect had a median value of -$47500.0 in 2022 and averaged -$71666.7.
  • In the last 5 years, Opko Health's Exchange Rate Effect surged by 40769.23% in 2023 and then crashed by 86846.47% in 2024.
  • Opko Health's Exchange Rate Effect (Quarter) stood at -$1.3 million in 2021, then skyrocketed by 233.52% to $1.7 million in 2022, then tumbled by 57.5% to $723000.0 in 2023, then crashed by 868.46% to -$5.6 million in 2024, then soared by 94.31% to -$316000.0 in 2025.
  • Its Exchange Rate Effect stands at -$316000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $2.1 million for Q1 2025.